Imatinib treatments for CML have been found to shift immune responses to TH1 by increasing IFN-γ+ T cells [47] and cytotoxic NK cells [48]. The gene discussed is IFNG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.